← 返回

FAP(+) 成纤维细胞在伴有癌栓的肾细胞癌中协调肿瘤微环境重塑

英文原题:FAP(+) fibroblasts orchestrate tumor microenvironment remodeling in renal cell carcinoma with tumor thrombus.

查看英文原题

FAP(+) fibroblasts orchestrate tumor microenvironment remodeling in renal cell carcinoma with tumor thrombus.

PubMed 2025/10/23(内容时间) Nat Commun Q1 · IF 18.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

肿瘤血栓(TT)会恶化肾细胞癌(RCC)的预后并使手术复杂化,但其形成机制仍不清楚。在此,我们对伴或不伴TT的RCC患者的71个组织和48个切片进行了整合的单细胞和空间转录组分析。细胞和空间图谱揭示了以FAP + 成纤维细胞富集为特征的独特TT相关肿瘤微环境重塑。这些FAP + 成纤维细胞在空间上与侵袭性癌细胞相邻,并在体外促进其恶性表型。其丰度与功能性NK细胞呈负相关,提示其在肿瘤侵袭和免疫逃逸中的作用。此外,单细胞多组学分析将肿瘤周细胞确定为FAP + 成纤维细胞的来源,并描绘了周细胞-成纤维细胞转变背后的转录因子动态。最后,高水平的FAP + 成纤维细胞与不良预后相关,并预测对抗VEGF治疗的较弱反应。总之,我们的研究强调FAP + 成纤维细胞是伴TT的侵袭性RCC的驱动因素,提示了潜在的治疗靶点。

展开英文摘要原文

Tumor thrombus (TT) worsens prognosis and complicates surgery in renal cell carcinoma (RCC), yet its formation mechanisms remain unclear.

Here, we perform integrative single-cell and spatial transcriptomic analyses on 71 tissues and 48 sections from RCC patients with or without TT. The cellular and spatial atlas reveals distinct TT-associated tumor microenvironment remodeling characterized by the enrichment of FAP + fibroblasts. These FAP + fibroblasts are spatially contiguous to aggressive cancer cells and promote their malignant phenotypes in vitro. Their abundance inversely correlates with functional NK cells, suggesting roles in tumor invasion and immune evasion.

Furthermore, single-cell multiomics analysis identifies tumor pericytes as a source of FAP + fibroblasts and delineates transcription factor dynamics underlying pericyte-fibroblast transition.

Finally, high levels of FAP + fibroblasts are associated with poor prognosis and predict a weaker response to anti-VEGF-based therapy.

In conclusion, our study highlights FAP + fibroblasts as drivers of aggressive RCC with TT, suggesting potential therapeutic targets.

论文信息

作者
Ma J、Huang Y、Chen J、Li Y、Yao R、Li X、Liang Q、Chen X
第一作者单位
Tsinghua-Peking Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing, China.China
通讯作者单位
State Key Laboratory of Medical Proteomics, National Center for Protein Sciences (Beijing), Research Unit of Proteomics Driven Cancer Precision Medicine (Chinese Academy of Medical Sciences), Beijing, China. hefc@bmi.ac.cn.China
期刊
Nature communications2025 Oct 23
原文标识
PubMed 41130981 · DOI 10.1038/s41467-025-64447-2